





BIOCORP launches Easylog, the first-ever add-on to convert insulin delivery systems into internet-connected devices

In order to improve patients' adherence to diabetes treatments, Biocorp has developed the first-ever system compatible with all insulin pens in the market that connects them to a treatment management mobile app.

Issoire (France) — October 6th, 2015 — **BIOCORP, a French company specializing in the development and manufacturing of innovative medical and drug delivery devices** (FR12788065 — ALCOR / PEA-PME eligible) introduces Easylog, its new add-on to improve diabetic patients' adherence to insulin injections. The first internet-connected system of its kind, Easylog attaches to the insulin pen, which, with 51.5 million users worldwide and an average annual growth of 13%, is now the most popular mode of treatment among diabetic patients¹.

"Having gained recognition with our innovative DataPen, the first-ever smart injection pen, we intensified our R&D efforts with the intention to expand the scope of our disruptive technologies to dynamic markets with strong growth potential. Today, this strategy allows us to provide manufacturers with a practical, internet-connected, easy-to-use solution that is compatible with existing insulin delivery devices and meets the challenges of personalized medicine. With this innovation, we seek once again to promote a better management of chronic diseases by bringing comfort to patients, empowering doctors and caregivers to ensure that the right treatments are given at the right time with the right dose, and by creating value for our pharmaceutical partners," said Jacques Gardette, Biocorp's President and founder.

A unique, patented technology whose design has been registered — a prototype of which was unveiled at the 2015 annual meeting of the European Association for the Study of Diabetes, in mid-September in Stockholm — EasyLog is an intelligent sensor that converts all insulin delivery devices, reusable as well as disposable, into internet-connected and communicating devices.



¹ Source: *Insulin Pen Market, Users (reusable & prefilled) & forecast, Worldwide analysis, Renub Research, 2014*



The data collected (insulin doses, patients' vital signs, etc.) are encrypted and made anonymous thanks to Biocorp's extensive know-how in health data security. These data are first stored on servers belonging to a secured and government-certified web host before being safely transferred to a mobile app similar to the one used for DataPen. This application provides users with treatment reminders, alerts in case of a risk of insulin overdose, and access to patients' historical data, among other services. Thanks to this real-time monitoring of the treatment, the patient is empowered to adhere to his treatment, while the medical staff can tailor individual treatment recommendations.

About BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand, France), Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as 'Innovative Company' by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 35 employees.

Biocorp is listed on Alternext since July 2015 (FR12788065 – ALCOR). For more information, please visit: www.biocorp.fr

Follow us on Twitter@BIOCORPSystems

Contacts

BioCorp

Jacques Gardette
Chairman & CEO
investisseurs@biocorp.fr

Eric Dessertenne
Head of Commercial Operations
and Business Development

Press relations

ALIZE RP

Claire Flin & Caroline Carmagnol
+33 1 44 64 36 66 / +33 6 95 41 95 90
biocorp@alizerp.com

Investors relations

Citigate Dewe Rogerson

Nicolas Castex & Lucie Larguier
+33 1 53 32 84 75
biocorp@citigate.fr